Alpha 2.0
Login Register
» Articles » PMID: 20973146

Second-generation BCR-ABL Kinase Inhibitors in CML

Overview
Journal N Engl J Med
Specialty General Medicine
Date 2010 Oct 26
PMID 20973146
Citations 5
Authors
Yavuz Beyazit
Murat Kekilli
Ibrahim C Haznedaroglu
Affiliations
Soon will be listed here.
Citing Articles

HS-543 induces apoptosis of Imatinib-resistant chronic myelogenous leukemia with T315I mutation.

Kim S, Jung K, Yan H, Son M, Fang Z, Ryu Y Oncotarget. 2014; 6(3):1507-18.

PMID: 25483100 PMC: 4359310. DOI: 10.18632/oncotarget.2837.

Anti-rheumatic agent auranofin induced apoptosis in chronic myeloid leukemia cells resistant to imatinib through both Bcr/Abl-dependent and -independent mechanisms.

Chen X, Shi X, Zhao C, Li X, Lan X, Liu S Oncotarget. 2014; 5(19):9118-32.

PMID: 25193854 PMC: 4253423. DOI: 10.18632/oncotarget.2361.

Monitoring the Response to Tyrosine Kinase Inhibitor (TKI) Treatment in Chronic Myeloid Leukemia (CML).

Haznedaroglu I Mediterr J Hematol Infect Dis. 2014; 6(1):e2014009.

PMID: 24455118 PMC: 3894837. DOI: 10.4084/MJHID.2014.009.

Gambogic acid induces apoptosis in imatinib-resistant chronic myeloid leukemia cells via inducing proteasome inhibition and caspase-dependent Bcr-Abl downregulation.

Shi X, Chen X, Li X, Lan X, Zhao C, Liu S Clin Cancer Res. 2013; 20(1):151-63.

PMID: 24334603 PMC: 3938960. DOI: 10.1158/1078-0432.CCR-13-1063.

Allografting for Bosutinib, Imatinib, Nilotinib, Dasatinib, and Interferon Resistant Chronic Myeloid Leukemia without ABL Kinase Mutation.

Uz B, Bektas O, Eliacik E, Goker H, Erbilgin Y, Sayitoglu M Case Rep Hematol. 2012; 2011:263725.

PMID: 22937303 PMC: 3420724. DOI: 10.1155/2011/263725.